421 related articles for article (PubMed ID: 34997254)
1. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.
Davies J; Siebenhandl-Wolff P; Tranquart F; Jones P; Evans P
Arch Toxicol; 2022 Feb; 96(2):403-429. PubMed ID: 34997254
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Layne KA; Dargan PI; Archer JRH; Wood DM
Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
[TBL] [Abstract][Full Text] [Related]
3. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
McDonald JS; McDonald RJ
Magn Reson Imaging Clin N Am; 2020 Nov; 28(4):497-507. PubMed ID: 33040991
[TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI.
Costelloe CM; Amini B; Madewell JE
Semin Ultrasound CT MR; 2020 Apr; 41(2):170-182. PubMed ID: 32446430
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
Delfino R; Biasotto M; Candido R; Altissimo M; Stebel M; Salomè M; van Elteren JT; Vogel Mikuš K; Zennaro C; Šala M; Addobbati R; Tromba G; Pascolo L
Toxicol Lett; 2019 Feb; 301():157-167. PubMed ID: 30476537
[TBL] [Abstract][Full Text] [Related]
6. Toxicological Risk Assessments of Iron Oxide Nanocluster- and Gadolinium-Based T1MRI Contrast Agents in Renal Failure Rats.
Weng Q; Hu X; Zheng J; Xia F; Wang N; Liao H; Liu Y; Kim D; Liu J; Li F; He Q; Yang B; Chen C; Hyeon T; Ling D
ACS Nano; 2019 Jun; 13(6):6801-6812. PubMed ID: 31141658
[TBL] [Abstract][Full Text] [Related]
7. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
8. Where does the gadolinium go? A review into the excretion and retention of intravenous gadolinium.
Sharma P; Cheng J; Coulthard A
J Med Imaging Radiat Oncol; 2023 Oct; 67(7):742-752. PubMed ID: 37665796
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Patient with Reported Gadolinium-Associated Illness.
Lyapustina T; Goldfine C; Rhyee S; Babu KM; Griswold MK
J Med Toxicol; 2019 Jan; 15(1):36-44. PubMed ID: 30499040
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-based contrast agents: A comprehensive risk assessment.
Fraum TJ; Ludwig DR; Bashir MR; Fowler KJ
J Magn Reson Imaging; 2017 Aug; 46(2):338-353. PubMed ID: 28083913
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
[TBL] [Abstract][Full Text] [Related]
13. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
[TBL] [Abstract][Full Text] [Related]
14. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.
Noda SM; Oztek MA; Stanescu AL; Maloney E; Shaw DWW; Iyer RS
Pediatr Radiol; 2022 Feb; 52(2):345-353. PubMed ID: 33978802
[TBL] [Abstract][Full Text] [Related]
17. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
[TBL] [Abstract][Full Text] [Related]
18. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
Bhave G; Lewis JB; Chang SS
J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
[TBL] [Abstract][Full Text] [Related]
19. [Kidney and iodinated and gadolinium-based contrast agents].
Clément O; Faye N; Fournier L; Siauve N; Frija G
J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.
Mathur M; Jones JR; Weinreb JC
Radiographics; 2020; 40(1):153-162. PubMed ID: 31809230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
